| [1] |
朱金海,左泽平,宇洪涛,等.术前外周血中淋巴细胞与单核细胞比值对高危非肌层浸润性膀胱癌预后的评估价值[J/OL].中华腔镜泌尿外科杂志(电子版), 2022, 16(2): 124-127.
|
| [2] |
Zazzara M, Nazaraj A, Scarcia M, et al. Electromotive drug administration of mitomycin c (emda/mmc) versus intravesical immunotherapy with bacillus calmette-guérin (bcg) in intermediate and high risk non muscle invasive bladder cancer[J]. Urol Int, 2023, 107(1): 64-71.
|
| [3] |
Racioppi M, Di Gianfrancesco L, Ragonese M, et al. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes [J]. BMC Cancer, 2018, 18(1): 1224.
|
| [4] |
De Jong JJ, Hendricksen K, Rosier M, et al. Hyperthermic intravesical chemotherapy for bcg unresponsive non-muscle invasive bladder cancer patients[J]. Bladder Cancer, 2018, 4(4): 395-401.
|
| [5] |
Dinney CP, Greenberg RE, Steinberg GD. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin [J]. Urol Oncol-Semin Ori, 2013, 31(8): 1635-42.
|
| [6] |
Hurle R, Contieri R, Casale P, et al. Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure [J]. Urol Oncol -Semin Ori, 2021, 39(3): 195.e7-195.e13.
|
| [7] |
Messing EM, Tangen CM, Lerner SP, et al. Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence swog s0337 randomized clinical trial [J]. JAMA, 2018, 319(18): 1880-1888.
|
| [8] |
Daneshmand S, Brummelhuis ISG, Pohar KS, et al. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial [J]. Urol Oncol, 2022, 40(7): 344 e1- e9.
|
| [9] |
Shantharam G, Amin A, Pereira J, et al. Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after bacillus calmette-guerin failure [J]. Curr Urol, 2021, 15(1): 33-8.
|
| [10] |
Arends TJH, Alfred Witjes J. Apaziquone for nonmuscle invasive bladder cancer: where are we now?[J]. Urol Clin North Am, 2020, 47(1): 73-82.
|
| [11] |
McKiernan JM, Holder DD, Ghandour RA, et al. Phase II Trial of Intravesical Nanoparticle Albumin Bound Paclitaxel for the Treatment of Nonmuscle Invasive Urothelial Carcinoma of the Bladder after bacillus Calmette-Guerin Treatment Failure [J]. J Urol, 2014, 192(6): 1633-1638.
|
| [12] |
Mckiernan JM, Onyeji I, Lascano D, et al. A phase I/II study of albumin-bound rapamycin nanoparticles in the treatment of bacillus calmette-guerin refractory non-muscle invasive transitional cell bladder cancer [J]. J Clin Oncol, 2016, 34(15): e16008.
|
| [13] |
Chevli KK, Shore ND, Trainer A, et al. Primary chemoablation of low-grade intermediate-risk nonmuscle-invasive bladder cancer using ugn-102, a mitomycin-containing reverse thermal gel (optima ii): a phase 2b, open-label, single-arm trial [J]. J Urol, 2022, 207(1): 61-68.
|
| [14] |
Hurle R, Guazzoni G, Colombo P, et al. Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start[J]. Urol Oncol, 2022, 40(1): 11.e9-11.e15.
|
| [15] |
Morales A, Chin JL, Ramsey EW. Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder [J]. J Urol, 2001, 166(5): 1633-1637.
|
| [16] |
Morales A, Phadke K, Steinhoff G. Intravesical mycobacterial cell wall-dna complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed [J]. J Urol, 2009, 181(3): 1040-1045.
|
| [17] |
Ahn JJ, Ghandour RA, McKiernan JM. New agents for bacillus Calmette-Guerin-refractory nonmuscle invasive bladder cancer [J]. Curr Opin Urol, 2014, 24(5): 540-545.
|
| [18] |
Miyazaki J, Nishiyama H, Yano I, et al. The therapeutic effects of r8-liposome-bcg-cws on bbn-induced rat urinary bladder carcinoma[J]. Anticancer Res, 2011, 31(6): 2065-2071.
|
| [19] |
Whang YM, Yoon DH, Hwang GY, et al. Liposome-encapsulated bacillus calmette-guerin cell wall skeleton enhances antitumor efficiency for bladder cancer in vitro and in vivo via induction of amp-activated protein kinase [J]. Cancers, 2020, 12(12): 3679.
|
| [20] |
Tang C, Liu H, Fan Y, et al. Functional nanomedicines for targeted therapy of bladder cancer [J]. Front Pharmacol, 2021, Nov 16(12): 778973.
|
| [21] |
Rentsch CA, Thalmann GN, Lucca I, et al. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14[J]. Eur Urol Oncol, 2022, 5(2): 195-202.
|
| [22] |
Lammers RJ, Witjes WP, Janzing-Pastors MH, et al. Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial[J]. J Clin Oncol, 2012, 30(18): 2273-9.
|
| [23] |
Kowalski M, Entwistle J, Cizeau J, et al. A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients[J]. Drug Des Devel Ther, 2010, 4: 313-20.
|
| [24] |
Kowalski M, Guindon J, Brazas L, et al. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin[J]. J Urol, 2012, 188(5): 1712-8.
|
| [25] |
董文. 肌层浸润性膀胱癌新辅助与辅助免疫治疗的现状与展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(1): 1-6.
|
| [26] |
Woodcock VK, Purshouse K, Butcher C, et al. A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC) [J]. J Clin Oncol, 2019, 37(7): 406.
|
| [27] |
Hahn NM, O'Donnell MA, Efstathiou JA, et al. A phase 1 trial of durvalumab in combination with bacillus calmette-guerin (bcg) or external beam radiation therapy in patients with bcg-unresponsive non-muscle-invasive bladder cancer: the hoosier cancer research network gu16-243 adapt-bladder study [J]. Eur Urol, 2023, 83(6): 486-494.
|
| [28] |
Black PC, Tangen C, Singh P, et al. Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816). ASCO2021[J]. J Clin Oncol, 2021, 39(15): 4541-4541.
|
| [29] |
Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions[J]. MAbs, 2010, 2(2): 129-136.
|
| [30] |
Huang J, Schisler J, Wong HC, et al. Intravesical ALT-803 for BCG-unresponsive bladder cancer - a case report[J]. Urol Case Rep, 2017, 14: 15-17.
|
| [31] |
Huang J, Shiao SL, Furuya H, et al. Immunogenomic analysis of exceptional responder to ALT-803 (il-15 analogue) in bcg unresponsive nonmuscle invasive bladder cancer: a case series and review of the literature [J]. J Immunother, 2019, 42(9): 354-358.
|
| [32] |
Ward K, Kitchen MO, Mathias SJ, et al. Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning [J]. Front Surg, 2022, 9: 912438.
|
| [33] |
Burke JM, Lamm DL, Meng MV, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer[J]. J Urol, 2012, 188(6): 2391-7.
|
| [34] |
Packiam VT, Lamm DL, Barocas DA, et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non muscle-invasive bladder cancer: Interim results [J]. Urol Oncol -Semin Ori, 2018, 36(10): 440-447.
|
| [35] |
Shore ND, Boorjian SA, Canter DJ, et al. Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study[J]. J Clin Oncol, 2017, 35(30): 3410-3416.
|
| [36] |
Boorjian SA, Alemozaffar M, Konety BR, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial [J]. Lancet Oncol, 2021, 22(1): 107-117.
|
| [37] |
Gofrit ON, Benjamin S, Halachmi S, et al. DNA based therapy with diphtheria toxin-A BC-819: a phase 2b marker lesion trial in patients with intermediate risk nonmuscle invasive bladder cancer[J]. J Urol, 2014, 191(6): 1697-702.
|